---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-046052"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T04:24:04.240286+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kyverna reports 2024 net loss $127.5M; cash runway into 2027; SPS trial 70% enrolled

## Summary
- Net loss of $127.5M ($3.33 loss per share) for full year 2024 vs $60.4M loss in 2023.
- Cash, equivalents and marketable securities $286.0M as of Dec 31, 2024; expected runway into 2027.
- FDA aligned on registrational Phase 2 design for KYV-101 in stiff person syndrome; 70% enrolled, topline data 1H 2026.
- Phase 2 interim data in myasthenia gravis and Phase 1 data in lupus nephritis expected in 2H 2025.
- KYV-102 IND filing planned for 2H 2025; management team and board strengthened.

## SEC filing metadata
- accession: 0000950170-25-046052
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000095017025046052/0000950170-25-046052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000095017025046052/kytx-20250327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-046052
- JSON: https://secwatch.observer/filing/0000950170-25-046052.json
- Plain text: https://secwatch.observer/filing/0000950170-25-046052.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.